文献速递类风湿关节炎脊柱关节炎其他结缔组织病

肿瘤坏死因子抑制剂药物安全性与免疫原性:迄今研究进展

Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

综述评估肿瘤坏死因子抑制剂(TNFi)免疫原性与药物安全性,梳理抗药抗体与输液反应、血栓栓塞事件、狼疮样综合征、矛盾性不良事件(如血管炎样事件)等关联。生物类似药引入与切换、TNFi减量等策略可能影响免疫原性与临床结局,文中归纳试验、自发药物警戒与观察性研究证据并指出不确定领域。

要点

  • TNFi具免疫原性,抗药抗体形成可影响疗效与安全性。
  • 抗药抗体与输液反应相关,也报道有血栓栓塞、狼疮样综合征及矛盾性不良事件。
  • 生物类似药切换与TNFi减量等策略可能影响免疫原性与临床结局。

核心结论

  • TNFi免疫原性与药物安全性仍存在争议和不确定领域。
  • 生物类似药引入与切换、TNFi减量等策略可能对免疫原性和临床后遗症产生影响。

研究设计与样本

  • 综述评估生物制剂演变与药物安全性及免疫原性的关系,证据来自试验、自发药物警戒和观察性研究。

主要发现

  • 多数TNFi具免疫原性,抗药抗体形成可影响治疗疗效与安全性。
  • TNFi抗药抗体与输液反应相关,也报道有血栓栓塞事件、狼疮样综合征、矛盾性不良事件(如血管炎样事件)及其他自身免疫表现。
  • 生物类似药引入与切换、TNFi减量等策略可能影响免疫原性与临床结局。

局限性

  • 文中指出仍存在不确定领域。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TNF-α inhibitor (TNFi) therapies have transformed the treatment of several rheumatic musculoskeletal diseases. However, the majority of TNFi's are immunogenic and consequent anti-drug antibodies formation can impact on both treatment efficacy and safety. Several controversies exist in the area of immunogenicity of TNFis and drug safety. While anti-drug antibodies to TNFis have been described in association with infusion reactions; serious adverse events (AEs) such as thromboembolic events, lupus-like syndrome, paradoxical AEs, for example, vasculitis-like events and other autoimmune manifestations have also been reported. The expansion of the biologic armamentarium, new treatment strategies such as introduction/switching to biosimilars and cost-saving approaches such as TNFi tapering, may all have a potential impact on immunogenicity and clinical sequelae. In this review we evaluate how evolution of biologics relates to drug safety and immunogenicity, appraise relevant evidence from trials, spontaneous pharmacovigilance and observational studies and outline the areas of uncertainty that still exist.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Jani M, Dixon WG, Chinoy H, et al. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. Rheumatology (Oxford). 2018. PMID: 29325166. doi:10.1093/rheumatology/kex434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。